A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia

• Published in: The Egyptian journal of internal medicine Vol. 36; no. 1; pp. 69 - 12
• Main Authors: Olatunji, Gbolahan, Kokori, Emmanuel, Moradeyo, Abdulrahmon Akanmu, Lema, Kaleb, Ayo, Olanipekun Ridwan, Obasanjo, Opabode Muntaqim, Mustapha, Mubarak Jolayemi, Stanley, Anthony Chidera, Aderinto, Nicholas
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 26.06.2024; Springer Nature B.V; SpringerOpen
• Subjects: Apheresis; Cardiovascular disease; Case reports; Cholesterol; Clinical trials; Evinacumab; Familial Hypercholesterolemia; High density lipoprotein; Human subjects; Internal Medicine; Lipids; Low density lipoprotein receptors; Medicine; Medicine & Public Health; Metabolism; Monoclonal antibodies; Patients; Review; Familial Hypercholesterolemia; Evinacumab; Cholesterol
• ISSN: 2090-9098; 1110-7782; 2090-9098
• DOI: 10.1186/s43162-024-00335-3

Background Familial hypercholesterolemia (FH) poses a substantial risk of cardiovascular diseases. The recent approval of evinacumab signifies a breakthrough in FH management. This review synthesizes evidence from diverse clinical trials, examining evinacumab’s efficacy, safety, and broader impact on hypercholesterolemia. Body As highlighted by multiple trials, Evinacumab demonstrates robust efficacy in reducing LDL-C levels, particularly in refractory cases. Its sustained impact, evidenced by enduring reductions in LDL-C levels throughout extended treatment periods, positions it as a potential long-term solution. While the safety profile appears favorable, instances of deaths underline the importance of holistic clinical management and ongoing surveillance. The clinical implications are profound, suggesting evinacumab’s potential inclusion in guidelines for managing severe lipid disorders. Conclusion Future research directions emphasize inclusivity, diversity, and real-world applications to establish sustained efficacy and safety across diverse populations. Integrating evinacumab into clinical guidelines requires evidence-based recommendations, necessitating collaboration between researchers, clinicians, and guideline developers.